Hyundai Pharm (004310) - Total Liabilities

Latest as of February 2026: ₩89.49 Billion KRW ≈ $60.65 Million USD

Based on the latest financial reports, Hyundai Pharm (004310) has total liabilities worth ₩89.49 Billion KRW (≈ $60.65 Million USD) as of February 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Hyundai Pharm - Total Liabilities Trend (2010–2025)

This chart illustrates how Hyundai Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore Hyundai Pharm (004310) investment intensity to see how much of total assets are deployed in long-term investments.

Hyundai Pharm Competitors by Total Liabilities

The table below lists competitors of Hyundai Pharm ranked by their total liabilities.

Company	Country	Total Liabilities
Heidelberg Pharma AG F:HPHA	Germany	€43.94 Million
MagnaChip Semiconductor NYSE:MX	USA	$102.66 Million
Petrochemical TA:PTCH	Israel	ILA641.07 Million
D&D Platform Reit Co Ltd KO:377190	Korea	₩683.38 Billion
Innate Pharma NASDAQ:IPHA	USA	$84.39 Million
MOLECULAR PARTNERS ADS/1 F:6ML0	Germany	€21.77 Million
American Well Corp NYSE:AMWL	USA	$85.84 Million
Takarék Jelzálogbank Nyrt F:FH21	Germany	€682.66 Billion

Liability Composition Analysis (2010–2025)

This chart breaks down Hyundai Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Hyundai Pharm balance sheet assets.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.28	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.66	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.40	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Hyundai Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Hyundai Pharm (2010–2025)

The table below shows the annual total liabilities of Hyundai Pharm from 2010 to 2025.

Year	Total Liabilities	Change
2025-11-30	₩81.11 Billion ≈ $54.97 Million	+4.90%
2024-11-30	₩77.32 Billion ≈ $52.40 Million	+10.51%
2023-11-30	₩69.97 Billion ≈ $47.42 Million	-26.04%
2022-11-30	₩94.60 Billion ≈ $64.11 Million	+22.45%
2021-11-30	₩77.26 Billion ≈ $52.36 Million	+14.69%
2020-11-30	₩67.36 Billion ≈ $45.65 Million	+16.35%
2019-11-30	₩57.89 Billion ≈ $39.23 Million	+11.77%
2018-11-30	₩51.80 Billion ≈ $35.10 Million	-8.35%
2017-11-30	₩56.52 Billion ≈ $38.30 Million	+11.99%
2016-11-30	₩50.47 Billion ≈ $34.20 Million	+19.61%
2013-11-30	₩42.19 Billion ≈ $28.59 Million	-15.98%
2012-11-30	₩50.22 Billion ≈ $34.03 Million	-4.59%
2011-11-30	₩52.63 Billion ≈ $35.67 Million	+36.79%
2010-11-30	₩38.48 Billion ≈ $26.08 Million	--

About Hyundai Pharm

KO:004310 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$133.25 Million

₩196.63 Billion KRW

Market Cap Rank

#18157 Global

#794 in Korea

Share Price

₩6360.00

Change (1 day)

+3.41%

52-Week Range

₩3545.00 - ₩14340.00

All Time High

₩14340.00